within Pharmacolibrary.Drugs.ATC.N;

model N05AE05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.09,
    Cl             = 6.5,
    adminDuration  = 600,
    adminMass      = 0.04,
    adminCount     = 1,
    Vd             = 0.317,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007333333333333333,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Lurasidone is an atypical antipsychotic medication approved for the treatment of schizophrenia and bipolar depression in adults and adolescents. It acts primarily as an antagonist at dopamine D2, serotonin 5-HT2A, and 5-HT7 receptors. Lurasidone is currently approved and widely used.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for lurasidone in healthy adult subjects after oral administration. Data mainly reflect single-dose administration of 40 mg under fed conditions.</p><h4>References</h4><ol><li><p>Hu, C, et al., &amp; Jia, J (2017). Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects. <i>Clinical drug investigation</i> 37(9) 861–871. DOI:<a href=&quot;https://doi.org/10.1007/s40261-017-0546-8&quot;>10.1007/s40261-017-0546-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28695535/&quot;>https://pubmed.ncbi.nlm.nih.gov/28695535</a></p></li><li><p>Chiu, YY, et al., &amp; Loebel, A (2014). Lurasidone drug-drug interaction studies: a comprehensive review. <i>Drug metabolism and drug interactions</i> 29(3) 191–202. DOI:<a href=&quot;https://doi.org/10.1515/dmdi-2014-0005&quot;>10.1515/dmdi-2014-0005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24825095/&quot;>https://pubmed.ncbi.nlm.nih.gov/24825095</a></p></li><li><p>Lee, KR, et al., &amp; Koo, TS (2011). Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 41(12) 1100–1107. DOI:<a href=&quot;https://doi.org/10.3109/00498254.2011.603388&quot;>10.3109/00498254.2011.603388</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21838595/&quot;>https://pubmed.ncbi.nlm.nih.gov/21838595</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05AE05;
